 - subjects presenting type IIa or IIb primary hypercholesterolaemia diagnosed for at least 3 months, in a context of primary prevention with at least two associated cardiovascular risk factors and: ieither naive to all lipid-lowering therapy, iior treated with a statin treatment ongoing or stopped during the previous 8 weeks 